GSK plc - 16 Jun 2021 Form 3 Insider Report for 23andMe Holding Co. (MEHCQ)

Role
10%+ Owner
Signature
/s/ Victoria Whyte, Authorized Signatory, GSK plc
Issuer symbol
MEHCQ
Transactions as of
16 Jun 2021
Net transactions value
$0
Form type
3
Filing time
04 Nov 2022, 16:11:57 UTC
Previous filing
24 May 2021
Next filing
23 Jun 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ME Class B Common Stock 16 Jun 2021 Class A Common Stock 39,660,487 $0.000000 See Footnote F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the post Share Conversion Ratio (which is equal to 2.293698) number shares of Class B common stock, par value $0.0001, of 23andMe Holding Co. (the "Issuer"), acquired due to the completion of the merger between Issuer (f/k/a VG Acquisition Corp. ("VGAC")), Chrome Merger Sub, Inc., a Delaware corporation and wholly owned direct subsidiary of VGAC ("Merger Sub"), and 23andMe, Inc., a Delaware corporation ("23andMe"), (the "Business Combination") pursuant to the Agreement and Plan of Merger, dated as of February 4, 2021.
F2 The shares reported herein are held of record by Glaxo Group Limited, an indirect, wholly-owned subsidiary of GSK plc (the "Reporting Person").
F3 Shares of Class B Common Stock, which are not registered under the Securities Exchange Act of 1934, as amended, are convertible into shares of Class A Common Stock on a share-for-share basis at any time at the option of the holder. The Class B ordinary shares have no expiration date.